{"article": [{"url": "https://www.marketwatch.com/story/rigels-stock-jumps-25-after-announcing-uk-trial-for-possible-covid-19-treatment-2020-07-14", "published": 1594713440.0, "headline": "Rigel's stock jumps 25% after announcing U.K. trial for possible COVID-19 treatment", "body": "Shares of Rigel Pharmaceuticals Inc. RIGL, -1.15% gained 25% in premarket trading on Tuesday after announcing that a drug used to treat an autoimmune disorder will be tested in a clinical trial in the United Kingdom as a treatment for COVID-19 pneumonia. The Imperial College London will operate the open-label, controlled trial for Tavalisse, which received Food and Drug Administration approval for chronic immune thrombocytopenia in 2018. Patients will receive Tavalisse, the chemotherapy ruxolitinib, or the standard of care, with a goal of understanding whether the drug can prevent the progression of mild or moderate COVID-19 pneumonia to more severe disease. Rigel's stock is down 0.9% year-to-date, while the S&P 500 SPX, +0.87% has declined 2.3%."}]}